Business Wire (08/18/15)

A new survey from Quantia looked at physician attitudes toward biosimilars, including their awareness of the drugs, potential barriers to adoption, and opportunities to provide education that may drive prescribing decisions. Overall, the report found that 94 percent of physician respondents believe biosimilars will provide value to healthcare, largely because of their lower costs to patients and the health system. However, just 17 percent of prescribing specialists said they would be "very likely" to prescribe biosimilars to eligible patients. Their primary concerns include safety/efficacy, drug substitution regulations, and accurate evaluation of when to prescribe a biosimilar vs. branded therapy. Meanwhile, specialty societies were prescribing specialists' most trusted source of information about biosimilars, followed by peers and key opinion leaders. "The survey findings confirm that many physicians already recognize the potential clinical value and cost savings that biosimilars represent, and many are hopeful that these therapies will soon be viable for their patient populations," said Dan Malloy, executive vice president of Quantia.

Web Link 

Abstract News © 2015 INFORMATION, INC.

Access other Therapeutic Areas:


 

New & Noteworthy